Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-cash Items (2017 - 2024)

Historic Non-cash Items for Protagonist Therapeutics (PTGX) over the last 8 years, with Q4 2024 value amounting to $152.9 million.

  • Protagonist Therapeutics' Non-cash Items rose 15483.33% to $152.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $152.9 million, marking a year-over-year increase of 15483.33%. This contributed to the annual value of $152.9 million for FY2024, which is 15483.33% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Non-cash Items stood at $152.9 million for Q4 2024, which was up 15483.33% from $60.0 million recorded in Q4 2023.
  • Over the past 5 years, Protagonist Therapeutics' Non-cash Items peaked at $152.9 million during Q4 2024, and registered a low of $2.2 million during Q1 2020.
  • Moreover, its 5-year median value for Non-cash Items was $4.1 million (2022), whereas its average is $32.5 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first surged by 291363.64% in 2021, then tumbled by 9494.84% in 2022.
  • Protagonist Therapeutics' Non-cash Items (Quarter) stood at $40.0 million in 2020, then soared by 156.75% to $102.7 million in 2021, then plummeted by 93.28% to $6.9 million in 2022, then skyrocketed by 769.57% to $60.0 million in 2023, then surged by 154.83% to $152.9 million in 2024.
  • Its last three reported values are $152.9 million in Q4 2024, $60.0 million for Q4 2023, and $4.4 million during Q2 2023.